science
Acting Director of FDA Drug Center Tracy Beth Høeg Leaves Agency
Tracy Beth Høeg, acting director of the Food and Drug Administration’s Center for Drug Evaluation and Research, is departing the agency. The departure comes days after Commissioner Marty Makary submitted his resignation. Michael Davis, the center’s current deputy director, will assume the role of acting director.
May 15, 5:52 PM·1m read1 source
StatAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources familiar with the matter. The departure comes days after Commissioner Marty Makary handed in his resignation. Michael Davis, currently the center’s deputy director, will take over as acting director.
The FDA and Høeg did not immediately respond to requests for comment. Reuters and Bloomberg first reported the news.
The changes leave the agency facing a leadership vacuum at a time when it oversees regulation of pharmaceuticals and public health decisions. Høeg had been serving in the acting director role for the drug center. Her exit follows the commissioner’s resignation by only a few days, according to the sources.
The FDA did not provide further details on the reasons for the departures or on any timeline for appointing permanent leadership.
